Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
Shares of (NASDAQ: MRNA) recently did some bouncing around. The company posted results on the morning of Nov. 2, and the stock lost more than 10% when the market opened. Luckily, positive economic data pushed up biotech stocks in general and wiped away the previous day's losses.
This isn't the first time falling sales of its COVID-19 vaccine, Spikevax, led shares of Moderna lower. The stock is down about 84% from the high-water mark it set over two years ago. While this has been upsetting to long-term shareholders, it could also mean the stock has been beaten down too far.
By the end of 2024, there's a good chance Spikevax won't be Moderna's only source of recurring revenue. Does a pipeline poised to deliver new vaccines make this a good stock to buy right now? Let's weigh reasons to avoid the biotech against reasons to buy it and find out.
Source Fool.com
Moderna Inc. Aktie
Die Community bevorzugt klar Moderna Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Moderna Inc. mit einem Kursziel von 129 € im Vergleich zum aktuellen Kurs von 65.76 € zu erwarten.
